| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Hypothesis |
Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 [K. E. N.]; Hospital for Sick Children, Toronto, Ontario, M5G 1X8 Canada [D. M.]; Dana Farber Cancer Institute, Boston, Massachusetts 02115 [J. E. G., F. P. L.]; and Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892 [J. F. F.]
Germ-line p53 mutations are associated with dominantly inherited Li-Fraumeni syndrome (LFS), which features early-onset sarcomas of bone and soft tissues, carcinomas of the breast and adrenal cortex, brain tumors, and acute leukemias. However, carriers of germ-line p53 mutations may also be at increased risk of other cancers. To clarify the tumor spectrum associated with inherited p53 mutations, we examined cancer occurrences among our series of 45 families, plus 140 other affected cases and kindreds reported in the literature. The analyses included all cancers in patients with a germ-line p53 mutation and their first-degree relatives with nearly 50% likelihood of being a carrier. Data were abstracted on tumor types and ages at diagnosis in eligible family members, and duplicate reports were excluded. Among 738 evaluable cancers, 569 (77%) were the six tumor types (breast and adrenocortical carcinomas, sarcomas of the bone and soft tissues, brain tumors, and leukemias) associated with LFS. The remaining 169 (23%) cancers included diverse carcinomas of the lung and gastrointestinal tract, lymphomas, and other neoplasms that occurred at much earlier ages than expected in the general population. Unusually early ages at diagnosis are characteristic of hereditary cancers and suggest that carriers of germ-line p53 mutations are at increased risk of a wide range of neoplasms. Future studies addressing age-specific penetrance and site-specific cancer risks can increase the utility of LFS as a model for understanding the role of p53 alterations in carcinogenesis and for designing diagnostic and preventive interventions for the broad array of neoplasms in this syndrome.
This article has been cited by other articles:
|
|
 |
|
  D. C. Allain Genetic Counseling and Testing for Common Hereditary Breast Cancer Syndromes: A Paper from the 2007 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2008; 10(5): 383 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shlien, U. Tabori, C. R. Marshall, M. Pienkowska, L. Feuk, A. Novokmet, S. Nanda, H. Druker, S. W. Scherer, and D. Malkin Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome PNAS, August 12, 2008; 105(32): 11264 - 11269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Masciari, A. D. Van den Abbeele, L. R. Diller, I. Rastarhuyeva, J. Yap, K. Schneider, L. Digianni, F. P. Li, J. F. Fraumeni Jr, S. Syngal, et al. F18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Screening in Li-Fraumeni Syndrome JAMA, March 19, 2008; 299(11): 1315 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zhang, T. Sun, L. Xue, X. Han, B. Zhang, N. Lu, Y. Shi, W. Tan, Y. Zhou, D. Zhao, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer Carcinogenesis, May 1, 2007; 28(5): 1067 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Wu, S. Shete, C. I. Amos, and L. C. Strong Joint Effects of Germ-Line p53 Mutation and Sex on Cancer Risk in Li-Fraumeni Syndrome Cancer Res., August 15, 2006; 66(16): 8287 - 8292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Walsh, S. Casadei, K. H. Coats, E. Swisher, S. M. Stray, J. Higgins, K. C. Roach, J. Mandell, M. K. Lee, S. Ciernikova, et al. Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer JAMA, March 22, 2006; 295(12): 1379 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Caldas, M P Holloway, B M Hall, S J Qualman, and R A Altura Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo J. Med. Genet., February 1, 2006; 43(2): 119 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Travis, C. S. Rabkin, L. M. Brown, J. M. Allan, B. P. Alter, C. B. Ambrosone, C. B. Begg, N. Caporaso, S. Chanock, A. DeMichele, et al. Cancer Survivorship--Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations J Natl Cancer Inst, January 4, 2006; 98(1): 15 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Debniak, B Gorski, T Huzarski, T Byrski, C Cybulski, A Mackiewicz, S Gozdecka-Grodecka, J Gronwald, E Kowalska, O Haus, et al. A common variant of CDKN2A (p16) predisposes to breast cancer J. Med. Genet., October 1, 2005; 42(10): 763 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Garber and K. Offit Hereditary Cancer Predisposition Syndromes J. Clin. Oncol., January 10, 2005; 23(2): 276 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Liang, X. Miao, Y. Zhou, W. Tan, and D. Lin A functional polymorphism in the SULT1A1 gene (G638A) is associated with risk of lung cancer in relation to tobacco smoking Carcinogenesis, May 1, 2004; 25(5): 773 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Fletcher, D. Easton, K. Anderson, C. Gilham, M. Jay, and J. Peto Lifetime Risks of Common Cancers Among Retinoblastoma Survivors J Natl Cancer Inst, March 3, 2004; 96(5): 357 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Nichols, J. A. Heath, D. Friedman, J. A. Biegel, A. Ganguly, P. Mauch, and L. Diller TP53, BRCA1, and BRCA2 Tumor Suppressor Genes Are Not Commonly Mutated in Survivors of Hodgkin's Disease With Second Primary Neoplasms J. Clin. Oncol., December 15, 2003; 21(24): 4505 - 4509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Hill, P. D. Inskip, W. R. Shapiro, R. G. Selker, H. A. Fine, P. M. Black, and M. S. Linet Cancer in First-Degree Relatives and Risk of Glioma in Adults Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1443 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Olivier, D. E. Goldgar, N. Sodha, H. Ohgaki, P. Kleihues, P. Hainaut, and R. A. Eeles Li-Fraumeni and Related Syndromes: Correlation between Tumor Type, Family Structure, and TP53 Genotype Cancer Res., October 15, 2003; 63(20): 6643 - 6650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wrensch, Y. Minn, T. Chew, M. Bondy, and M. S. Berger Epidemiology of primary brain tumors: Current concepts and review of the literature Neuro-oncol, October 1, 2002; 4(4): 278 - 299. [Abstract] [PDF]
|
|
|
|
 |
|
 T. K. MacLachlan, R. Takimoto, and W. S. El-Deiry BRCA1 Directs a Selective p53-Dependent Transcriptional Response towards Growth Arrest and DNA Repair Targets Mol. Cell. Biol., June 15, 2002; 22(12): 4280 - 4292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Smith and Y. R. Seo p53 regulation of DNA excision repair pathways Mutagenesis, March 1, 2002; 17(2): 149 - 156. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
